JAMA: The addition of P2Y12 inhibitors to heparin therapy is not beneficial for improving the prognosis of hospitalized patients with new coronary pneumonia

The COVID-19 pandemic has brought unprecedented challenges to the global healthcare system
.
While most hospitalized patients are not critically ill and do not require intensive care-level medical support, multiple randomized clinical trials have shown that 24% of noncritically ill patients died or received intensive care treatment after receiving therapeutic doses of heparin, whereas Abnormal coagulation function is more common in critically ill patients with new coronary pneumonia , suggesting that new treatment methods are needed for critically ill patients with new coronary pneumonia

.

COVID-19 COVID-19 Researchers recently examined the benefits and risks of adding a P2Y12 inhibitor to anticoagulation in non-critically ill patients hospitalized with Covid-19

The mean number of days without organ support was 21 days (range 20-21) in the 2Y12 group and 21 days (range 21-22 days) in the control group, with an adjusted OR=0.

For non-critically hospitalized patients with new coronary pneumonia, adding a P2Y12 inhibitor to the therapeutic dose of heparin will not improve the patient's prognosis, but will increase the patient's risk of major bleeding
.
For non-critically hospitalized patients with new coronary pneumonia, adding a P2Y12 inhibitor to the therapeutic dose of heparin will not improve the patient's prognosis, but will increase the patient's risk of major bleeding
.

Original Source:
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19 A Randomized Clinical Trial.
JAMA Comments Here